Last updated: August 6, 2024
Sponsor: Freeline Therapeutics
Overall Status: Active - Recruiting
Phase
1/2
Condition
Gaucher Disease
Treatment
FLT201
Clinical Study ID
NCT06545136
FLT201-02
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Participants who have previously received FLT201 (including those who may haverequired recommencement or initiation of ERT/substrate reduction therapy [SRT]).
- Participants able to give full informed consent and able to comply with allrequirements of the trial.
Exclusion
Exclusion Criteria:
- n/a
Study Design
Total Participants: 75
Treatment Group(s): 1
Primary Treatment: FLT201
Phase: 1/2
Study Start date:
May 13, 2024
Estimated Completion Date:
May 31, 2029
Connect with a study center
Hospital de Clinicas de Porto Alegre (HCPA)
Porto Alegre,
BrazilSite Not Available
Hospital Quironsalud Zaragoza
Zaragoza,
SpainActive - Recruiting
Salford Royal Hospital
Salford,
United KingdomSite Not Available
Lysosomal Rare Disorders Research and Treatment Center
Fairfax, Virginia 22030-6066
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.